Faeth Posts $20.4M Q3 Loss, Cash at $174.8M Ahead of Year-End PIKTOR Data
FTH has more than doubled off its 52-week low of $7.45.
Summary
Faeth reported a Q3 2026 net loss of $20.4 million, or $0.79 per share, versus a $4.6 million loss a year earlier, as R&D jumped to $11.7 million from $2.5 million and G&A rose to $10.4 million from $2.3 million. Cash, cash equivalents and marketable securities stood at $174.8 million on September 30, 2026, up from $21.2 million at year-end 2025 — a substantial runway cushion for a company this size. The quarter's news flow was mostly already public: the FDA Fast Track designation for PIKTOR plus paclitaxel in biomarker-selected endometrial cancer (reported in August) and the board additions of Karen Vousden and Adam Schayowitz (disclosed in September and October 8-Ks). The real swing factor is the Phase 2 PIK-201 topline data in second-line advanced endometrial cancer, guided to year-end 2026, with initial PIK-101 breast cancer data pushed to 2027. Watch the PIK-201 readout — that binary event, not this quarter's burn, is what sets the stock's direction.
At the time of this announcement, FTH was trading at $19.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $496.9M. The 52-week trading range was $7.45 to $42.14. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: BusinessWire.